论文部分内容阅读
维奈克拉的应用是近年来治疗急性髓系白血病（AML）的重要突破。诱导凋亡药物联合去甲基化药物这一非化疗手段应用于AML的治疗，给老年或不能耐受强化疗的患者带来了长期生存的希望，但目前仍有一部分患者会对含维奈克拉的方案出现耐药。文章结合第62届美国血液学会（ASH）年会报道对维奈克拉治疗AML的新进展进行介绍。“,”Venetoclax is an important breakthrough in the treatment of acute myeloid leukemia (AML) in recent years. A chemo-free treatment of inducing apoptosis drugs combined with hypomethylating agents is used in the management of AML, which brings hope of long-term survival for the elderly patients or patients who cannot tolerate intensive chemotherapy. However, there are still some patients who are resistant to venetoclax-based regimens. This article introduces the new progress of venetoclax in the treatment of AML in combination with reports at the 62nd American Society of Hematology (ASH) Annual Meeting.